Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design

V2, Crosslink

🧫

Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-non-dopa

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design ## Background and Rationale This comprehensive study challenges the traditional dopamine-centric view of Parkinson's disease by systematically investigating the temporal sequence and clinical impact of non-dopaminergic neurotransmitter system degeneration. Growing evidence suggests that noradrenergic, serotonergic, cholinergic, and GABAergic systems may be affected early in PD pathogenesis, potentially driving many non-mo

METHODOLOGY NOTES

## **Phase 1: Cross-Sectional Neurochemical Mapping (Months 1-12)** Recruit 200 PD patients across disease stages (50 each: de novo, early [H&Y 1-2], moderate [H&Y 3], advanced [H&Y 4-5]) and 50 age-matched controls from 6 movement disorder centers. Perform comprehensive neurotransmitter system mapping using PET imaging: [11C]MeNER for noradrenaline transporter, [11C]DASB for serotonin transporter, [18F]FEOBV for vesicular acetylcholine transporter, and [11F]flumazenil for GABA-A receptors. Conduct DaTscan SPECT for dopamine transporter reference. Measure plasma and CSF neurotransmitter metabolites: MHPG (noradrenaline), 5-HIAA (serotonin), choline (acetylcholine), and GABA levels using HPLC-MS/MS. ## **Phase 2: Longitudinal Progression Tracking (Months 6-48)** Follow cohort with annual PET imaging and clinical assessments over 4 years. Primary clinical measures: MDS-UPDRS (motor and non-motor), cognitive assessment battery (attention, executive function, memory), sleep studies (polys

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.900821Z'}
summary	# Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design ## Background and Rationale This comprehensive study challenges the traditional dopamine-centric view of Parkinson's disease
entities	{'genes': ['NDNS'], 'diseases': ["Parkinson's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design
methodology_notes	## Phase 1: Cross-Sectional Neurochemical Mapping (Months 1-12) Recruit 200 PD patients across disease stages (50 each: de novo, early [H&Y 1-2], moderate [H&Y 3], advanced [H&Y 4-5]) and 50 age-m
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.900825', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

703

Outgoing

664

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Design

derives from (16)

supports (65)

💬 Discussion